Margarita Romeo

Badalona, CT 08916, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications

A rise in double-strand breaks sensitizes tumors to oxidative metabolism inhibitors.

A rise in double-strand breaks sensitizes tumors to oxidative metabolism inhibitors.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: January 09, 2026

Addressing unmet needs in long-term survivors of ovarian cancer (ENGOT ov40/NOGGO S13/GEICO 71-R/Expression VI): insights from a Spanish cohort.

Addressing unmet needs in long-term survivors of ovarian cancer (ENGOT ov40/NOGGO S13/GEICO 71-R/Expression VI): insights from a Spanish cohort.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: July 30, 2025

Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.

Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 18, 2024

Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy.

Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy.

Journal: International journal of molecular sciences
Published: September 17, 2024

Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status.

Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status.

Journal: British journal of cancer
Published: August 01, 2024

Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer : Alexandra Leary.

Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer : Alexandra Leary.

Journal: BMC cancer
Published: July 29, 2024

Deciphering HER2-low breast cancer (BC): insights from real-world data in early stage breast cancer.

Deciphering HER2-low breast cancer (BC): insights from real-world data in early stage breast cancer.

Journal: Therapeutic advances in medical oncology
Published: July 13, 2024

Polypharmacy and Reversible Drug Induced QT Prolongation in a Patient with Advanced Cancer: Case Report.

Polypharmacy and Reversible Drug Induced QT Prolongation in a Patient with Advanced Cancer: Case Report.

Journal: Journal of pain & palliative care pharmacotherapy
Published: January 05, 2024

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer.

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer.

Journal: BMC cancer
Published: January 02, 2024

The spatial landscape of cancer hallmarks reveals patterns of tumor ecological dynamics and drug sensitivity.

The spatial landscape of cancer hallmarks reveals patterns of tumor ecological dynamics and drug sensitivity.

Journal: Cell reports
Published: October 21, 2023

Prognostic Value of Lymph Node Ratio in Patients with Uterine Carcinosarcoma.

Prognostic Value of Lymph Node Ratio in Patients with Uterine Carcinosarcoma.

Journal: Journal of personalized medicine
Published: October 18, 2023

Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery.

Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery.

Journal: International journal of molecular sciences
Published: June 05, 2023
Showing 1-12 of 32

Last Updated: 09/26/2026